Recently, Fosun Omni, subordinated under Fosun Pharmaceutical, has concluded cooperation agreement with Aurobindo, a global pharmaceutical manufacturer from India, for three Controlled-Release Projects in the field of the Cardiovascular for a purpose of jointly developing the markets North America and Europe as well as the emerging markets in China and India.

Fosun Omni is an R&D company, which is established in China and oriented towards mainstream medical markets in Europe and US, as well as gives consideration to the markets in China and focus on demanding Generic Drug and new drugs of sustained and controlled-release and respiratory tract administration system in conformity with Euramerican Standards; India’s Aurobindo is one of the most progressive pharmaceutical manufacturers in the world over the recent years, especially in North America with protruding performance, it has signed strategic cooperation agreement with Pfizer recently , Fosun Omni and Aurobindo will jointly tap the markets in three sustained and controlled-release projects, at present, the global market value of these three project is not less than US$ 550 million, additionally, they will discuss and negotiate the cooperation on sustained and controlled-release projects in other fields. President Mr. Rendy of Aurobindo will make a special trip to China to discuss the matters for comprehensive cooperation on respiratory tract administration.

The President of Fosun Omni has expressed that cooperating with Aurobindo, a global pharmaceutical manufacturer from India, to jointly develop demanding projects is a kind approve to advancement of the technologies and R&D capability from international large-scale pharmaceutical manufacturers, this company will continue to make great efforts on demanding Generic Drug and develop global markets.